Conversion.
An important aspect of assessing the efficacy of the outcome of the primary and secondary treatment trials concerns the topic of conversion. That is, how does one assess an end point such as the transition from normal to mild cognitive impairment (MCI) or the progression of MCI to Alzheimer disease (AD)? These can be difficult issues, but as more is learned about the intermediate states such as MCI, criteria can be developed.
Petersen
Ronald C
RC
Department of Neurology and the Mayo Alzheimer Disease Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. peter8@mayo.edu
D000544:Alzheimer Disease / Q000150:complications / Q000175:diagnosis* / Q000523:psychology; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology / Q000523:psychology; D018450:Disease Progression; D006801:Humans